| PAH | High risk | P value |
---|---|---|---|
Participants, n | 14 | 6 | Â |
Female (%) | 11 (79) | 5 (83) | 0.98 |
Age, years | 54 ± 14 | 63 ± 7.6 | 0.18 |
BSA, m2 | 1.79 ± 0.25 | 1.83 ± 0.17 | 0.79 |
PAH aetiology (%) | |||
 Idiopathic | 10 (71) |  |  |
 CTD-associated | 4 (29) |  |  |
Coexisting conditions (%) | |||
 Diabetes mellitus | 2 (14) | 0 (0) | <0.05 |
 Smoker | 1 (12) | 0 (0) | <0.05 |
 CTD | 5 (36) | 5 (83) | <0.05 |
NYHA functional class (%) | |||
 II | 3 (21) | 6 (100) | <0.05 |
 III | 11 (79) | 0 (0) | <0.05 |
Therapy, initial/follow-up (%) | |||
 Phosphodiesterase-5 inhibitor | 1 (7)/0 (0) |  |  |
 Combination | 13 (93)/14 (100) |  |  |
Creatinine, μmol/L | 84 ± 21 | 83 ± 34 | 0.96 |
DLCO, % | 55 ± 15 | 58 ± 19 | 0.76 |
%FVC/%DLCO | 1.41 ± 0.41 | 1.38 ± 0.27 | 0.92 |